Literature DB >> 29075830

Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.

Han Soo Yoo1, Seok Jong Chung1, Su Jin Chung1, Hyojeong Moon2, Jung Su Oh2, Jae Seung Kim2, Jin Yong Hong3, Byoung Seok Ye1, Young Ho Sohn1, Phil Hyu Lee4.   

Abstract

PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset.
METHODS: From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years. Based on the time from PD onset, LID was classified as early, intermediate or late onset. We then compared DAT availability in the striatal subregions of the patients in the three groups.
RESULTS: The demographic characteristics did not differ among the three patient groups except for earlier intervention of levodopa therapy in the early LID onset group (p = 0.001). After adjusting for age at PD onset, gender, timing of levodopa therapy from PD onset, and the severity of PD motor symptoms, DAT activity in the posterior putamen was found to be significantly lower in the early LID onset group than in the late LID onset group (p = 0.017). Multivariate linear regression analysis showed that low DAT activity in the posterior putamen was significantly associated with the early appearance of LID in the early LID onset group (β = 16.039, p = 0.033).
CONCLUSION: This study demonstrated that low DAT activity in the posterior putamen at baseline is a major risk factor for the early onset of LID in patients with PD, suggesting that the degree of presynaptic dopaminergic denervation plays an important role in determining the timing of LID onset.

Entities:  

Keywords:  Dopamine transporter; Levodopa-induced dyskinesia; PET; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 29075830     DOI: 10.1007/s00259-017-3844-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  58 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

2.  Dopamine transporters decrease with age.

Authors:  N D Volkow; Y S Ding; J S Fowler; G J Wang; J Logan; S J Gatley; R Hitzemann; G Smith; S D Fields; R Gur
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

3.  Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

Authors:  M Péchevis; C E Clarke; P Vieregge; B Khoshnood; C Deschaseaux-Voinet; G Berdeaux; M Ziegler
Journal:  Eur J Neurol       Date:  2005-12       Impact factor: 6.089

Review 4.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

5.  Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.

Authors:  J S Schneider
Journal:  Pharmacol Biochem Behav       Date:  1989-09       Impact factor: 3.533

6.  Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum.

Authors:  O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

7.  N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter.

Authors:  U Scheffel; J R Lever; P Abraham; K R Parham; W B Mathews; T Kopajtic; F I Carroll; M J Kuhar
Journal:  Synapse       Date:  1997-04       Impact factor: 2.562

8.  A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

Authors:  M Lundblad; B Picconi; H Lindgren; M A Cenci
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

Review 9.  Levodopa-induced dyskinesias.

Authors:  Giovanni Fabbrini; Jonathan M Brotchie; Francisco Grandas; Masahiro Nomoto; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-07-30       Impact factor: 10.338

10.  [123I]FP-CIT SPET imaging in drug-induced Parkinsonism.

Authors:  Michele Tinazzi; Sarah Ottaviani; Ioannis U Isaias; Isabella Pasquin; Maria Steinmayr; Claudio Vampini; Manuela Pilleri; Giuseppe Moretto; Antonio Fiaschi; Nicola Smania; Piergiorgio Giorgetti; Angelo Antonini
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

View more
  10 in total

1.  Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop
Journal:  Exp Neurol       Date:  2020-05-05       Impact factor: 5.330

2.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

Review 3.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

Review 4.  Molecular Imaging of the Dopamine Transporter.

Authors:  Giovanni Palermo; Roberto Ceravolo
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

5.  Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.

Authors:  Yang Hyun Lee; Jungho Cha; Seok Jong Chung; Han Soo Yoo; Young H Sohn; Byoung Seok Ye; Phil Hyu Lee
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

6.  Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.

Authors:  Han Soo Yoo; Yong Ho Choi; Seok Jong Chung; Yang Hyun Lee; Byoung Seok Ye; Young H Sohn; Jong-Min Lee; Phil Hyu Lee
Journal:  Ann Clin Transl Neurol       Date:  2019-10-23       Impact factor: 4.511

Review 7.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 8.  Mitochondrial Dysfunction in Parkinson's Disease: From Mechanistic Insights to Therapy.

Authors:  Xiao-Yan Gao; Tuo Yang; Ying Gu; Xiao-Hong Sun
Journal:  Front Aging Neurosci       Date:  2022-06-20       Impact factor: 5.702

9.  Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.

Authors:  Han Soo Yoo; Eun-Chong Lee; Seok Jong Chung; Byoung Seok Ye; Young H Sohn; Joon-Kyung Seong; Phil Hyu Lee
Journal:  Sci Rep       Date:  2022-07-25       Impact factor: 4.996

10.  Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort.

Authors:  Paolo Eusebi; Michele Romoli; Federico Paolini Paoletti; Nicola Tambasco; Paolo Calabresi; Lucilla Parnetti
Journal:  NPJ Parkinsons Dis       Date:  2018-11-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.